The human brain remains medicine’s greatest mystery. Doctors can track almost every organ in the body through simple, non-invasive tests, but when it comes to the brain, even basic monitoring still demands surgical procedures. A young UK-based company named CoMind now wants to change that reality. With over $100 million in fresh funding, CoMind stands on the edge of transforming how doctors measure brain health — without drills, bolts, or the risks of invasive surgery.
From Teenage Vision to Medtech Trailblazer
When James Dacombe first imagined CoMind, he was still a teenager who believed technology could solve one of medicine’s most invasive problems. He wanted to monitor the brain safely, painlessly, and continuously. That idea grew into a company in 2018, and after years of patient research, prototype development, and clinical testing, CoMind has become one of the UK’s most promising deep-tech startups.
Now, with a fresh $60 million funding round led by the venture capital firm Plural, CoMind’s total funding exceeds $102 million. Investors believe Dacombe and his team have cracked a problem that has challenged neuroscientists for decades: how to monitor key brain metrics — like blood flow and intracranial pressure — without drilling through the skull.
The Technology That Could Redefine Brain Monitoring
Today, doctors use invasive methods to measure pressure inside the skull or track blood flow in the brain. The procedure involves drilling a small hole in the skull and inserting a pressure bolt. While this approach saves lives, it also carries serious risks. Around 15 percent of patients who undergo invasive intracranial monitoring experience complications such as infections, bleeding, or swelling.
CoMind’s technology eliminates those dangers. The company’s non-drill device uses low-powered infrared lasers to capture data from deep within the brain. The system measures how light reflects and scatters through brain tissue, translating that data into precise information about cerebral blood flow, intracranial pressure, and cerebral autoregulation — three vital indicators of brain health.
By using light instead of metal bolts, CoMind removes the need for surgery, lowers risk, and potentially allows doctors to monitor many more patients who currently go without critical data. The device could one day sit gently against a patient’s scalp, continuously reading brain activity while they rest in a hospital bed or even at home.
A Huge Unmet Clinical Need
In the United States alone, nearly three million people suffer from traumatic brain injuries (TBIs) every year. Yet, only about five percent of them receive invasive intracranial pressure monitoring. That means millions of patients go untreated or undiagnosed because the current procedure feels too risky or too costly for hospitals to perform routinely.
CoMind’s technology addresses that gap directly. By removing the drill, hospitals could monitor every patient with a serious brain injury, stroke, or swelling episode safely and quickly. This shift could save countless lives by allowing doctors to detect brain pressure changes early — long before symptoms appear.
Doctors could also use the technology in surgeries, intensive care units, or even emergency rooms. Ambulances or air ambulances could carry portable versions to monitor brain trauma on the spot. The possibilities stretch across every corner of modern medicine, from neurosurgery to critical care and sports medicine.
Why Investors See Massive Potential
The medtech market thrives on innovation that improves both safety and efficiency. CoMind’s device ticks both boxes. By cutting out invasive procedures, hospitals reduce risks, shorten recovery times, and free up surgical resources.
Investors also love technologies that redefine how medicine collects data. CoMind doesn’t just replace a single invasive test; it introduces continuous, real-time brain data. That data could reveal patterns doctors have never seen before — how the brain reacts to injury, anesthesia, or disease progression minute by minute.
This combination of deep science, scalable technology, and global need explains why investors poured money into CoMind. The latest round, led by Plural, brought together a mix of venture capital funds and medtech specialists who recognize the company’s potential to dominate a market with few competitors.
The Long Road to Market
Despite the excitement, CoMind still faces a demanding journey. Medical device development involves rigorous clinical trials, complex regulatory processes, and years of testing before doctors can use the product in hospitals.
CoMind has already completed two successful clinical trials in Europe. The company now plans to begin its third major trial in the United States, which will provide the data needed for FDA approval. If those trials deliver strong results, CoMind aims to launch its first commercial product by 2027.
The team continues to refine the device’s accuracy and usability. Engineers focus on improving sensor sensitivity, while clinical researchers fine-tune how the device interprets data in real-time. Every improvement brings CoMind closer to its mission — to make brain monitoring as simple as checking blood pressure.
Breaking Barriers in Deep-Tech Medtech
Most health startups build software platforms or wearable gadgets. CoMind operates in a different category — deep-tech medtech. This space combines physics, engineering, and clinical science to solve problems that software alone cannot touch. Developing such technology demands years of research and substantial capital, but when it works, it changes entire medical fields.
CoMind’s progress highlights a broader shift in health innovation. Investors increasingly back companies that merge hard science with healthcare impact. Instead of apps that track steps or heart rate, they want systems that directly influence hospital outcomes and save lives. CoMind’s infrared-based monitoring system fits perfectly into that new wave of medical innovation.
What Success Could Mean for Healthcare
If CoMind succeeds, hospitals worldwide could adopt non-invasive brain monitoring as a standard of care. Surgeons could track brain pressure during operations without opening the skull. Intensive care doctors could continuously observe patients with head injuries or brain swelling. Even neurologists could gain new insights into diseases like stroke, Alzheimer’s, or hydrocephalus.
The potential extends far beyond critical care. Non-invasive brain monitoring could open doors for research into how the brain responds to stress, sleep, or therapy. It could even support mental health studies by linking cerebral blood flow patterns to emotional states or cognitive function.
A breakthrough like this would transform brain medicine from reactive to proactive. Instead of waiting for symptoms or emergencies, doctors could track changes early and intervene before damage occurs.
The Challenges Ahead
For all its promise, CoMind must still overcome significant hurdles. Clinical validation remains the most critical step. Regulators demand proof that the device matches or exceeds the accuracy of invasive methods. Even small measurement errors can affect patient outcomes, so precision matters more than speed.
The company must also navigate adoption and reimbursement. Hospitals often hesitate to switch to new devices without clear cost benefits or insurance coverage. CoMind needs to demonstrate not only safety and accuracy but also financial value — fewer complications, shorter hospital stays, and reduced overall costs.
Finally, the team must manage expectations. Breakthrough technologies rarely move fast in healthcare. CoMind’s engineers and investors must remain patient as trials progress and approvals take time. However, every milestone brings them closer to a future where no patient needs a drilled hole in the skull just to measure brain pressure.
A Glimpse Into the Future
The idea that light can read the brain once sounded like science fiction. Now, CoMind’s progress proves that vision can become reality with enough persistence and innovation.
James Dacombe’s journey from teenage dreamer to medtech pioneer captures the spirit of modern entrepreneurship — curiosity, courage, and conviction in the face of complex science. With $100 million in funding, CoMind has the resources to push forward and redefine how medicine understands the brain.
If the company succeeds, hospitals may soon replace drills and bolts with beams of light. Doctors will gain safer, faster access to the brain’s secrets, and patients will face far fewer risks. CoMind doesn’t just build a device; it builds a bridge between technology and human resilience. And that bridge could change medicine forever.
Also Read – The Evolution of the Indian Startup Ecosystem (2010–2025)